IPSEN (OTCMKTS:IPSEY - Get Free Report) saw unusually-high trading volume on Monday . Approximately 5,170 shares traded hands during trading, an increase of 79% from the previous session's volume of 2,895 shares.The stock last traded at $43.23 and had previously closed at $44.63.
Wall Street Analysts Forecast Growth
IPSEY has been the topic of several recent research reports. UBS Group downgraded IPSEN from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 8th. BNP Paribas Exane lowered shares of IPSEN to an "underperform" rating in a report on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of IPSEN in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold".
Check Out Our Latest Stock Analysis on IPSEN
IPSEN Price Performance
The company has a 50-day simple moving average of $43.00 and a 200 day simple moving average of $37.88.
About IPSEN
(
Get Free Report)
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of ten stocks that are set to soar in 2026, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
